The recent first global approval of elsulfavirine has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Elsulfavirine (Elpida®): First Global Approval – a potential aid to the HIV epidemic in Russia”
The recent first global approval of enasidenib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Enasidenib (Idhifa®): First Global Approval – first-in-class, precision therapy for patients with mutated AML”
The recent first global approval of neratinib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?”
By Tim Wrightson, Editor, Applied Health Economics and Health Policy
The latest issue of Applied Health Economics and Health Policy includes three articles that contribute to the literature on the relationship between out-of-pocket (OOP) payments and the accessibility and affordability of healthcare. Continue reading “Out-of-Pocket Payments for Healthcare”